Top

Published in:

Open Access 01-05-2021 | Anemia | Nephrology - Review

Biomarkers of iron metabolism in chronic kidney disease

Authors: Glogowski Tomasz, Wojtaszek Ewa, Malyszko Jolanta

Published in: International Urology and Nephrology | Issue 5/2021

Abstract

Iron is the most abundant transition metal in the human body and an essential element required for growth and survival. Our understanding of the molecular control of iron metabolism has increased dramatically over the past 20 years due to the discovery of hepcidin, which regulates the uptake of dietary iron and its mobilization from macrophages and hepatic stores. Anemia and iron deficiency are common in chronic kidney disease. The pathogenesis of anemia of chronic kidney disease is multifactorial. Correction of anemia requires two main treatment strategies: increased stimulation of erythropoiesis, and maintenance of an adequate iron supply to the bone marrow. However, there are still many uncertainties in regard to iron metabolism in patients with chronic kidney disease and in renal replacement therapy. The aim of this review was to summarize the current knowledge on iron metabolism in this population, including new biomarkers of iron status. There is an area of uncertainty regarding diagnostic utility of both erythroferrone (ERFE) and hepcidin in end-stage renal disease (ESRD) patients. Higher concentration of hepcidin in oligoanuric patients may reflect decreased renal clearance. Furthermore, the hepcidin-lowering effect of ERFE in ESRD patients treated with erythropoiesis-stimulating agents (ESAs) may be blunted by underlying inflammation and concomitant iron treatment. Thus, future studies should validate the use of ERFE as a biomarker of erythropoiesis and predictor of response to iron and ESA therapy in dialysis-dependent patients.

Blanc B, Finch CA, Hallberg L, Herbert V, Lawkowicz W, Layrisse M, Mollin DL, Rachmilewitz M, Ramalingaswami V, Sanchez-Medal L, Vintrobe MM (1968) Nutritional anemias. Report of a WHO Scientific Group. WHO Tech Rep Ser 405:1–40. https://apps.who.int/iris/bitstream/handle/10665/40707/WHO_TRS_405.pdf;jsessionid=723826504327390B6E2BACE6A264BC23?sequence=1

Astor BC, Muntner P, Levin A, Eustace JA, Coresh J (2002) Association of kidney function with anemia, the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 162(12):1401–1408CrossRefPubMed

Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, Maruyama S, Wada T, Terada Y, Yamagata K, Narita I, Yanagita M, Sugiyama H, Shigematsu T, Ito T, Tamura K, Isaka Y, Okada H, Tsuruya K, Yokoyama H, Nakashima N, Hiromi K, Ohe K, Okada M, Kashihara N (2020) Prevalence of anemia in patients with chronic kidney disease in Japan: a nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS ONE 15(7):e0236132. https://doi.org/10.1371/journal.pone.0236132CrossRefPubMedPubMedCentral

Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. JASN 23(10):1631–1634. https://doi.org/10.1681/ASN.2011111078CrossRefPubMedPubMedCentral

Fishbane S, Spinowitz B (2018) Update on anemia in ESRD and earlier Stages of CKD: core curriculum. Am J Kidney Dis 71(3):423–435. https://doi.org/10.1053/j.ajkd.2017.09.026CrossRefPubMed

Filipczyk L, Król P, Wystrychowski A (2010) Hepcydyna—hormon wątrobowy kontrolujący gospodarkę żelaza. Forum Nefrologiczne 3(4):233–242. https://journals.viamedica.pl/forum_nefrologiczne/article/view/10359

Mazur G, Wróbel T, Nosol J (2005) Rola hepcydyny w regulacji homeostazy żelaza. Acta Haematologica Polonica 36(2):167–175. https://pthit.pl/Acta_Haematologica_Polonica,Hepcydyna_Hemochromatoza_Niedokrwistosc_w_przebiegu_chorob_przewleklych,250.html

Andrews NC (2008) Forging a field: the golden age iron biology. Blood 112(2):219–230. https://doi.org/10.1182/blood-2007-12-077388CrossRefPubMedPubMedCentral

Beaumont C, Delaby C (2009) Recycling iron in normal and pathological states. Semin Hematol 46(4):328–338. https://doi.org/10.1053/j.seminhematol.2009.06.004CrossRefPubMed

10.

Lipiński P, Starzyński R (2004) Regulacja ogólnoustrojowej homeostazy żelaza przez hepcydynę. Postępy Hig Med Dosw (online) 58:65–73. https://www.phmd.pl/api/files/view/1702.pdf

11.

Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276(11):7806–7810. https://doi.org/10.1074/jbc.m008922200CrossRefPubMed

12.

Camaschella C (2015) Iron-deficiency anemia. N Engl J Med 372:1832–1843. https://doi.org/10.1056/NEJMra1401038CrossRefPubMed

13.

Fleming RE, Ponka P (2012) Iron overload in human disease. N Engl J Med 366:348–359. https://doi.org/10.1056/NEJMra1004967CrossRefPubMed

14.

Casu C, Nemeth E, Rivella S (2018) Hepcidin agonists as therapeutic tools. Blood 131(16):1790–1794. https://doi.org/10.1182/blood-2017-11-737411CrossRefPubMedPubMedCentral

15.

Zhang A-S, Enns CA (2009) Molecular mechanisms of normal iron homeostasis. Hematology Am Soc Hematol Educ Program 2009:207–214. https://doi.org/10.1182/asheducation-2009.1.207CrossRef

16.

Hanudel MR, Rappaport M, Chua K, Gabayan V, Qiao B, Jung G, Salusky IB, Ganz T, Nemeth E (2018) Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica 103(4):e141–e142. https://doi.org/10.3324/haematol.2017.181743CrossRefPubMedPubMedCentral

17.

Hasegawa T, Koiwa F, Akizawa T (2018) Anemia in conventional hemodialysis: finding the optimal treatment balance. Semin Dial 31(6):599–606. https://doi.org/10.1111/sdi.12719CrossRefPubMed

18.

Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS (2007) Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117(7):1926–1932. https://doi.org/10.1172/jci31370CrossRefPubMedPubMedCentral

19.

Ueda N, Takasawa K (2018) Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients 10(9):1173. https://doi.org/10.3390/nu10091173CrossRefPubMedCentral

20.

Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M et al (2010) The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 152(10):640–648. https://doi.org/10.7326/0003-4819-152-10-201005180-00004CrossRefPubMedPubMedCentral

21.

Khan AM, Chirinos JA, Litt H, Yang W, Rosas SE (2012) FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol 7(12):2017–2022. https://doi.org/10.2215/cjn.02160212CrossRefPubMedPubMedCentral

22.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121(11):4393–4408. https://doi.org/10.1172/jci46122CrossRefPubMedPubMedCentral

23.

Mendoza MJ, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH et al (2012) Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 7(7):1155–1162. https://doi.org/10.2215/cjn.13281211CrossRef

24.

Wolf M, White KE (2014) Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23(4):411–419. https://doi.org/10.1097/01.mnh.0000447020.74593.6fCrossRefPubMedPubMedCentral

25.

Braithwaite V, Prentice AM, Doherty C, Prentice A (2012) FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol 2012(1):27. https://doi.org/10.1186/1687-9856-2012-27CrossRefPubMedPubMedCentral

26.

Deger SM, Erten Y, Pasaoglu OT, Derici UB, Reis KA, Onec K, Pasaoglu H (2013) The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol 17(3):416–423. https://doi.org/10.1007/s10157-012-0725-0CrossRefPubMed

27.

Nemeth E, Valore E, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood 101(7):2461–2463. https://doi.org/10.1182/blood-2002-10-3235CrossRefPubMed

28.

Wrighting DM, Andrews NC (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108(9):3204–3209. https://doi.org/10.1182/blood-2006-06-027631CrossRefPubMedPubMedCentral

29.

Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S (2002) Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 99(7):4596–4601. https://doi.org/10.1073/pnas.072632499CrossRefPubMedPubMedCentral

30.

Donderski R, Kardymowicz A, Manitius J (2009) Niedokrwistość nerkopochodna. Wybrane aspekty diagnostyki i terapii. Choroby Serca i Naczyń 6(2):82–93. https://journals.viamedica.pl/choroby_serca_i_naczyn/article/view/12052/9930

31.

Ganz T, Nemeth E (2016) Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol 36:87–93. https://doi.org/10.1016/j.semnephrol.2016.02.001CrossRefPubMedPubMedCentral

32.

Fasano A (2012) Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol 42(1):71–78. https://doi.org/10.1007/s12016-011-8291-xCrossRefPubMed

33.

Babitt JL, Lin HY (2012) Mechanism of anemia in CKD. J Am Soc Nephrol 23(10):1631–1634. https://doi.org/10.1681/ASN.2011111078CrossRefPubMedPubMedCentral

34.

Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1(suppl 1):S4–S8. https://doi.org/10.1159/000486968CrossRefPubMed

35.

Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L (2016) Iron deficiency anaemia. Lancet 387:907–916. https://doi.org/10.1016/S0140-6736(15)60865-0CrossRefPubMed

36.

The Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:279–335. https://doi.org/10.1038/kisup.2012.37CrossRef

37.

National Kidney Foundation (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47(5 Suppl 3):S11–S145. https://doi.org/10.1053/j.ajkd.2006.03.010CrossRef

38.

Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W, ERA-EDTA ERBP Advisory Board (2013) Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 28:1346–1359. https://doi.org/10.1093/ndt/gft033CrossRefPubMed

39.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T (2010) 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 14:240–275. https://doi.org/10.1111/j.1744-9987.2010.00836.xCrossRefPubMed

40.

Macginley R, Walker R, Irving M (2013) KHA-CARI guideline: use of iron in chronic kidney disease patients. Nephrology (Carlton) 18:747–749. https://doi.org/10.1111/nep.12139CrossRef

41.

Stancu S, Stanciu A, Zugravu A, Bârsan L, Dumitru D, Lipan M, Mircescu G (2010) Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis 55:639–647. https://doi.org/10.1053/j.ajkd.2009.10.043CrossRefPubMed

42.

Gaweda AE (2017) Markers of iron status in chronic kidney disease. Hemodial Int 21(Suppl 1):S21–S27. https://doi.org/10.1111/hdi.12556CrossRefPubMedPubMedCentral

43.

Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1(Suppl 1):S4–S8. https://doi.org/10.2215/CJN.01490506CrossRefPubMed

44.

Besarab A, Coyne DW (2010) Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 6:699–771. https://doi.org/10.1038/nrneph.2010.139CrossRefPubMed

45.

Hayes M (2019) Measurement of iron status in chronic kidney disease. Pediatr Nephrol 34:605–613. https://doi.org/10.1007/s00467-018-3955-xCrossRefPubMed

46.

Wong MMY, Tu C, Li Y, Pecoits-Filho R, Lopes AA, Narita I, Reichel H, Port FK, Sukul N, Stengel B, Robinson BM, Massy ZA, Pisoni RL, the CKDopps Investigators (2019) Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J 13:613–624. https://doi.org/10.1093/ckj/sfz091CrossRefPubMedPubMedCentral

47.

Fishbane S, Pollack S, Feldman HI, Joffe MM (2009) Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am Soc Nephrol 4:57–61. https://doi.org/10.2215/CJN.01670408CrossRefPubMedPubMedCentral

48.

Besarab A, Drueke TB (2020) The problem with trasferrin saturation as an indicator of iron “sufficiency” in chronic kidney disease. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfaa048CrossRef

49.

Kim T, Rhee CM, Streja E, Obi Y, Brunelli SM, Kovesdy CP, Kalantar-Zadeh K (2017) Longitudinal trends in serum ferritin levels and associated factors in a national incident hemodialysis cohort. Nephrol Dial Transplant 32:370–377. https://doi.org/10.1093/ndt/gfw012CrossRefPubMed

50.

Kalantar-Zadeh K, Rodriguez RA, Humphreys MH (2004) Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Naphrol Dial Transplant 19:141–149. https://doi.org/10.1093/ndt/gfg493CrossRef

51.

Ruiz-Jaramillo Mde L, Guizar-Mendoza JM, Amador-Licona N, de Jesus G-N, Hernández-González MA, Dubey-Ortega LA, Solorio-Meza SE (2011) Iron overload as cardiovascular risk factor in children and adolescents with renal disease. Nephrol Dial Transplant 26:3268–3273. https://doi.org/10.1093/ndt/gfr044CrossRefPubMed

52.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD, FIND-CKD Study Investigators (2014) FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 29:2075–2084. https://doi.org/10.1093/ndt/gfu201CrossRefPubMedPubMedCentral

53.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Meier Y, Larroque S, Perrin A, Roger SD (2017) Erythropoietic response to oral iron in patients with non-dialysis-dependent chronic kidney disease in FIND-CKD trial. Clin Nephrol 88:301–310. https://doi.org/10.5414/cn109198CrossRefPubMedPubMedCentral

54.

Takasawa K, Takeda C, Wada T, Ueda N (2018) Optimal serum ferritin levels for iron deficiency anemia during oral iron therapy (OIT) in Japanese hemodialysis patients with minor inflammation and benefit of intravenous iron therapy for OIT-nonresponders. Nutrients 10:428. https://doi.org/10.3390/nu10040428CrossRefPubMedCentral

55.

Singh AK, Coyne DW, Shapiro W, Rizkala AR, the DRIVE Study Group (2007) Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 71:1163–1171. https://doi.org/10.1038/sj.ki.5002223CrossRefPubMed

56.

Musanovic A, Trnacevic S, Mekic M, Musanovic A (2013) The influence of inflammatory markers and CRP predictive value in relation to target hemoglobin level in patients on chronic hemodialysis. Med Arch 67:361–364. https://doi.org/10.5455/medarh.2013.67.361-364CrossRefPubMed

57.

Tessitore N, Girelli D, Campostrini N, Bedogna V, Solero GP, Castagna A, Melilli E, Mantovani W, De Matteis G, Olivieri O, Poli A, Lupo A (2010) Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 25:3996–4002. https://doi.org/10.1093/ndt/gfq321CrossRefPubMed

58.

Suchdev PS, Williams AM, Mei Z, Flores-Ayala R, Pasricha SR, Rogers LM, Ml NS (1633S) Assessment of iron status in settings of inflammation: challenges and potential approaches. Am J Clin Nutr 106(Suppl 6):1626S–1633S. https://doi.org/10.3945/ajcn.117.155937CrossRefPubMedPubMedCentral

59.

Tarng DC, Huang TP (2002) Determinants of circulating soluble transferrin receptor level in chronic haemodialysis patients. Nephrol Dial Transplant 17:1063–1069. https://doi.org/10.1093/ndt/17.6.1063CrossRefPubMed

60.

Chiang WC, Tsai TJ, Chen YM, Lin SL, Hsieh BS (2002) Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol 58:363–369. https://doi.org/10.5414/cnp58363CrossRefPubMed

61.

Chen YC, Hung SC, Tarng DC (2006) Association between transferrin receptor—ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Am Kidney Dis 47:1036–1044. https://doi.org/10.1053/j.ajkd.2006.02.180CrossRef

62.

Hackeng CM, Beerenhout CM, Hermans M, Van der Kuy PHM, Van der Dussen H, Van Dieijen-Visser MP, Hamulyák K, Van der Sande FM, Leunissen KM, Koomanal JP (2004) The relationship between reticulocyte hemoglobin content with C-reactive protein and conventional iron parameters in dialysis patients. J Nephrol 17:107–111PubMed

63.

Bovy C, Tsobo C, Crapanzano L, Rorive G, Beguin Y, Albert A, Paulus JM (1999) Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int 56:1113–1119. https://doi.org/10.1046/j.1523-1755.1999.00627.xCrossRefPubMed

64.

Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G (2001) The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16:1416–1423. https://doi.org/10.1093/ndt/16.7.1416CrossRefPubMed

65.

Ratcliffe LE, Thomas W, Glen J, Padhi S, Pordes BAJ, Wonderling D, Connell R, Stephens S, Mikhail AI, Fogarty DG, Cooper JK, Dring B, Devonald MAJ, Brown C, Thomas ME (2016) Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale. Am J Kidney Dis 67:548–558. https://doi.org/10.1053/j.ajkd.2015.11.012CrossRefPubMed

66.

Chung M, Moorthy D, Hadar N, Salvi P, Iovin RC, Lau J (2012) Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease. Agency for Healthcare Research and Quality, Rockville. Report No.: 12(13)-EHC140-EF

67.

Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB (2009) Hepcidin—a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4:1051–1056. https://doi.org/10.2215/CJN.05931108CrossRefPubMedPubMedCentral

68.

Malyszko J, Malyszko JS, Kozminski P, Mysliwiec M (2009) Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin. Ren Fail 31:876–883. https://doi.org/10.3109/08860220903216071CrossRefPubMed

69.

Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB (2010) Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 5:1010–1014. https://doi.org/10.2215/CJN.08161109CrossRefPubMedPubMedCentral

70.

van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, Den Hoedt CH, Mazairac Albert HA, Nubé MJ, Lars Penne E, Gaillard CA, Wetzels JFM, Wiegerinck ET, Swinkels DW, Blankestijn PJ, ter Wee PM, CONTRAST investigator (2012) Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS ONE 7:e39783. https://doi.org/10.1371/journal.pone.0039783CrossRefPubMedPubMedCentral

71.

Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75:976–981. https://doi.org/10.1038/ki.2009.21CrossRefPubMed

72.

Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Froissart M, Stengel B (2014) The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS ONE 9:e99781. https://doi.org/10.1371/journal.pone.0099781CrossRefPubMed

73.

Łukaszyk E, Łukaszyk M, Koc-Żórawska E, Tobolczyk J, Bodzenta-Łukaszyk A, Małyszko J (2015) Iron status and inflammation in early stages of chronic kidney disease. Kidney Blood Press Res 40:366–373. https://doi.org/10.1159/000368512CrossRefPubMed

74.

Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A (2008) Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 28:115–121. https://doi.org/10.1159/000109968CrossRefPubMed

75.

Stefánsson BV, Abramson M, Nilsson U, Haraldsson B (2012) Hemodiafiltration improve plasma 25-hepcidin levels: a prospective, randomized, blinded, cross-over study comparing hemodialysis and hemodiafiltration. Nephron Extra 2:55–65. https://doi.org/10.1159/000336482CrossRefPubMedPubMedCentral

76.

Ford BA, Eby CS, Scott MG, Coyne Daniel W (2010) Intra-individual variability of serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 78:769–773. https://doi.org/10.1038/ki.2010.254CrossRefPubMed

77.

Peters HP, Rumjon A, Bansal SS, Laarakkers Coby MM, van den Brand JAJG, Sarafidis P, Musto R, Malyszko J, Swinkels DW, Wetzels JFM, Macdougall IC (2012) Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrol Dial Transplant 27:3923–3929. https://doi.org/10.1093/ndt/gfs164CrossRefPubMed

78.

Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Bansal SS, Cronin M, Meier Y, Larroque S, Roger SD, Macdougall IC (2016) Hepcidin response to iron therapy in patients with non-dialysis dependent CKD: an analysis of the FIND-CKD trial. PLoS ONE 11:e0157063. https://doi.org/10.1371/journal.pone.0157063CrossRefPubMedPubMedCentral

79.

Finkenstedt A, Widschwendter A, Brasse-Lagnel CG, Theurl I, Hubalek M, Dieplinger H, Tselepis C, Ward DG, Vogel W, Zoller H (2012) Hepcidin is correlated to soluble hemojuvelin but not increased GDF15 during pregnancy. Blood Cells Mol Dis 48:233–237. https://doi.org/10.1016/j.bcmd.2012.02.001CrossRefPubMed

80.

Malyszko J, Malyszko JS, Levin-Iaina N, Koc-Zorawska E, Kozminski P, Mysliwiec M (2011) Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients? Int Urol Nephrol 44:1805–1811. https://doi.org/10.1007/s11255-011-0084-xCrossRefPubMedPubMedCentral

81.

Rumjon A, Sarafidis P, Brincat S, Musto R, Malyszko J, Bansal SS, Macdougall IC (2012) Serum hemojuvelin and hepcidin levels in chronic kidney disease. Am J Nephrol 35:295–304. https://doi.org/10.1159/000336528CrossRefPubMed

82.

Lin L, Goldberg YP, Ganz T (2005) Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 106:2884–2889. https://doi.org/10.1182/blood-2005-05-1845CrossRefPubMed

83.

Silvestri L, Pagani A, Camaschella C (2008) Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 111:924–931. https://doi.org/10.1182/blood-2007-07-100677CrossRefPubMed

84.

Zhang AS, Anderson SA, Meyers KR, Hernandez C, Eisenstein RS, Enns CA (2007) Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem 282:12547–12556. https://doi.org/10.1074/jbc.M608788200CrossRefPubMed

85.

Gutiѐrrez OM, Sun CC, Chen W, Babitt JL, Lin HY (2012) Statement of concern about a commercial assay used to measure soluble hemojuvelin in humans. Am J Nephrol 36:332–333. https://doi.org/10.1159/000342519CrossRef

86.

Malyszko J, Koc-Żórawska E, Levin-Iaina N, Małyszko J, Koźmiński P, Kobus G, Myśliwiec M (2012) New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. Pol Arch Med Wewn 122:537–542PubMed

87.

Lakhal S, Talbot NP, Crosby A, Stoepker C, Townsend ARM, Robbins PA, Pugh CW, Ratcliffe PJ, Mole DR (2009) Regulation of growth differentiation factor 15 by intracellular iron. Blood 113:1555–1536. https://doi.org/10.1182/blood-2008-07-170431CrossRefPubMed

88.

Theurl I, Finkelstedt A, Schroll A, Nairz M, Sonnweber T, Bellmann-Weiler R, Theurl M, Seifert M, Wroblewski VJ, Murphy AT, Witcher D, Zoller H, Weiss G (2010) Growth differentiation factor in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Hematol 148:449–455. https://doi.org/10.1111/j.1365-2141.2009.07961.xCrossRef

89.

Breit SN, Carrero JJ, Tsai VW, Yagoutifam N, Luo W, Kuffner T, Bauskin AR, Wu L, Jiang L, Barany P, Heimburger O, Murikami MA, Apple FS, Marquis CP, Macia L, Lin S, Sainsbury A, Herzog H, Law M, Stenvinkel P, Brown DA (2012) Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant 27:70–75. https://doi.org/10.1093/ndt/gfr575CrossRefPubMed

90.

Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M (2009) Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 4:337–344. https://doi.org/10.2215/CJN.03530708CrossRefPubMedPubMedCentral

91.

Castillo-Rodriguez E, Fernandez-Prado R, Martin-Cleary C, Pizarro-Sánchez MS, Sanchez-Niño MD, Sanz AB, Fernandez-Fernandez B, Ortiz A (2017) Kidney injury marker 1 and neutrophil gelatinase-associated lipocalin in chronic kidney disease. Nephron 136:263–267. https://doi.org/10.1159/000447649CrossRefPubMed

92.

Kim IY, Kim JH, Lee DW, Lee SB, Rhee H, Song SH, Seong EY, Kwak IS (2018) Plasma neutrophil gelatinase-associated lipocalin is associated with iron status in anemic patients with predialysis chronic kidney disease. Clin Exp Nephrol 22:28–34. https://doi.org/10.1007/s10157-017-1409-6CrossRefPubMed

93.

Avci Cicek E, Rota S, Dursun B, Cavalci E (2016) Evaluation of serum NGAL and hepcidin levels in chronic kidney disease patients. Ren Fail 38:35–39. https://doi.org/10.3109/0886022X.2015.1107823CrossRefPubMed

94.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097CrossRefPubMedPubMedCentral

95.

Cappellini MD, Comin-Colet J, De Francisco A, Dignass A, Doehner W, Lam CS, Macdougall IC, Rogler G, Camaschella C, Kadir R, Kassebaum NJ, Spahn DR, Taher AT, Musallam KM, IRON CORE Group (2017) Iron deficiency across chronic inflammatory conditions: international expert opinion o definition, diagnosis and management. Am J Hematol 92(10):1068–1078. https://doi.org/10.1002/ajh.24820CrossRefPubMedPubMedCentral

96.

Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J (2019) Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets 23(5):407–421. https://doi.org/10.1080/14728222.2019.1599358CrossRefPubMed

97.

Wish JB, Aronoff GR, Bacon BR, Brugnara C, Eckardt KU, Ganz T, Macdougall IC, Núñez J, Perahia AJ, Wood JC (2018) Positive iron balance in chronic kidney disease: how much is too much and how to tell? Am J Nephrol 47(2):72–83. https://doi.org/10.1159/000486968CrossRefPubMed

98.

Nakanishi T, Kuragano T (2020) Potential hazards of recent trends in liberal iron use for renal anemia. Clin Kidney J. https://doi.org/10.1093/ckj/sfaa117CrossRefPubMedPubMedCentral

99.

Lenihan CR, Winkelmayer WC (2016) The dawning of a new day in CKD anemia care? J Am Soc Nephrol 27(4):968–970. https://doi.org/10.1681/ASN.2015091009CrossRefPubMed

100.

Bnaya A, Shavit L, Malyszko JS, Malyszko J, Slotki I (2020) Labile plasma iron levels in chronic hemodialysis patients treated by intravenous iron supplementation. Ther Apher Dial 24(4):416–422. https://doi.org/10.1111/1744-9987.13458CrossRefPubMed

101.

Cobo G, Lindholm B, Stenvinkel P (2018) Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant 33(suppl 3):iii35–iii40CrossRefPubMedPubMedCentral

102.

Appleby S, Chew-Harris J, Troughton RW, Richards AM, Pemberton CJ (2020) Analytical and biological assessment of circulating human erythroferrone. Clin Biochem 79:41–47. https://doi.org/10.1016/j.clinbiochem.2020.02.001CrossRefPubMed

Title: Biomarkers of iron metabolism in chronic kidney disease
Authors: Glogowski Tomasz
Wojtaszek Ewa
Malyszko Jolanta
Publication date: 01-05-2021
Publisher: Springer Netherlands
Keywords: Anemia
Iron Deficiency
Chronic Kidney Disease
Biomarkers
Published in: International Urology and Nephrology / Issue 5/2021
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-020-02663-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2021

Acute kidney injury associated with thymoma

Optimizing dialysis dose in the context of frailty: an exploratory study

Exercise interventions improve depression and anxiety in chronic kidney disease patients: a systematic review and meta-analysis

Adaptation, validity and reliability of geriatric self-efficacy index for urinary incontinence (GSE-UI) in geriatric incontinents

Physical performance and health-related quality of life among older adults on peritoneal dialysis: a cross-sectional study

Diagnosis and management of small intestinal injury due to percutaneous renal access

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials